Search Results

You are looking at 241 - 250 of 1,347 items for :

  • "characteristics" x
  • Refine by Access: All x
Clear All
Full access

Danielle S. Graham, Mykola Onyshchenko, Mark A. Eckardt, Benjamin J. DiPardo, Sriram Venigalla, Scott D. Nelson, Bartosz Chmielowski, Arun S. Singh, Jacob E. Shabason, Fritz C. Eilber, and Anusha Kalbasi

regression in each of these subgroup analyses. Statistical analysis was performed using STATA, version 15.1 (StataCorp LLP). Results Characteristics of Study Cohort Overall characteristics of the study cohort are summarized in Table 1 . Most patients were

Full access

Sapho X. Roodbeen, Marta Penna, Susan van Dieren, Brendan Moran, Paris Tekkis, Pieter J. Tanis, Roel Hompes, and on behalf of the International TaTME Registry Collaborative

procedures, or diagnosis other than adenocarcinoma on final histopathology; and 1,001 were treated in centers where >10% of their cases had ≥1 missing values for the main outcome parameters. Patient and tumor characteristics are outlined in Table 1 . Overall

Full access

Stefan W. Krause, Jan Schildmann, Christian Lotze, and Eva C. Winkler

oncology (72%). Many respondents reported having cared for inpatients and outpatients in the previous 6 months. Table 1 summarizes the respondents' characteristics and practice settings. Prevalence, Rationing Strategies, and Rationales for

Full access

Sierra Cheng, Matthew C. Cheung, Di Maria Jiang, Erica McDonald, Vanessa S. Arciero, Doreen Anuli Ezeife, Amanda Rahmadian, Alexandra Chambers, Kelley-Anne Sabarre, Ambika Parmar, and Kelvin K.W. Chan

scoring. Of these 127 RCTs, 108 RCTs comprising 116 treatment comparisons reported HR OS and were therefore included in the primary analysis. Key characteristics of the included RCTs are described in Table 1 . Figure 1. Process of screening and scoring

Full access

Puyao C. Li, Zilu Zhang, Angel M. Cronin, and Rinaa S. Punglia

the characteristics and prognosis of SBC. Patients and Methods Using the SEER database, 3,407 patients were identified who received BCS ± RT for primary DCIS in 2000 through 2013 and subsequently developed a stage I–III invasive SBC within the same

Full access

Kuan-Ling Kuo, David Stenehjem, Frederick Albright, Saurabh Ray, and Diana Brixner

at least 2 encounters in the EDW, with 1 encounter at least 30 days from the index date ( Figure 1 , available online, in this article, at JNCCN.org ). Demographic characteristics (age, sex, race, plan type, region) were recorded on index date and

Full access

Andrea Maurichi, Francesco Barretta, Roberto Patuzzo, Rosalba Miceli, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Martina Angi, Francesco Baldo Lanza, Giuseppe Spadola, Mara Cossa, Francesco Nesa, Umberto Cortinovis, Laura Sala, Lorenza Di Guardo, Carolina Cimminiello, Michele Del Vecchio, Barbara Valeri, and Mario Santinami

predictors associated with a more aggressive clinical behavior in patients with positive SNs, particularly with regard to metastatic involvement of further non-SNs. Some of these analyses of factors for higher invasiveness focused on characteristics of the

Full access

Adam J. Widman, Bevin Cohen, Vivian Park, Tara McClure, Jedd Wolchok, and Mini Kamboj

-agent pembrolizumab. No patients experienced a flare of a prior irAE after vaccination. Table 2 compares characteristics of patients who did versus did not experience an irAE. No significant differences in baseline characteristics or treatment were seen between

Full access

Joseph A. Greer, Jamie M. Jacobs, Nicole Pensak, Lauren E. Nisotel, Joel N. Fishbein, James J. MacDonald, Molly E. Ream, Emily A. Walsh, Joanne Buzaglo, Alona Muzikansky, Inga T. Lennes, Steven A. Safren, William F. Pirl, and Jennifer S. Temel

higher scores indicating greater perceived social support. Statistical Analyses SPSS Statistics, version 22.0 (IBM Corp) was used to conduct the analyses. Patient baseline characteristics were described using measures of central tendency or proportions

Full access

Amro M. Abdelrahman, Ajit H. Goenka, Roberto Alva-Ruiz, Jennifer A. Yonkus, Jennifer L. Leiting, Rondell P. Graham, Kenneth W. Merrell, Cornelius A. Thiels, Christopher L. Hallemeier, Susanne G. Warner, Michael G. Haddock, Travis E. Grotz, Nguyen H. Tran, Rory L. Smoot, Wen Wee Ma, Sean P. Cleary, Robert R. McWilliams, David M. Nagorney, Thorvardur R. Halfdanarson, Michael L. Kendrick, and Mark J. Truty

pathologic response and receiver operating characteristic (ROC) curves with area under the curve. To compare ROC curves for factors, we conducted paired-sample (ie, same patient) area under the curve statistical tests using a nonparametric assumption of